Medtecs International Corporation Ltd (9103) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Medtecs International Corporation Ltd TWD 1.92, price TWD 4.97, upside -61.4%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medtecs International Corporation Ltd DRC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 4.04 TWD – 37.00 TWD · fair‑value band 1.27 TWD – 2.40 TWD · the 4.97 TWD price screens above the 1.92 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Medtecs International Corporation Ltd DRC in your weekly email
Every Wednesday you see whether Medtecs International Corporation Ltd DRC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Medtecs International Corporation Limited, an integrated healthcare services provider, manufactures and distributes medical consumables for healthcare distributors, pharmaceutical companies, and hospital groups. It operates through Manufacturing, Hospital, and Distribution and Others segments.
Show more
Medtecs International Corporation Limited, an integrated healthcare services provider, manufactures and distributes medical consumables for healthcare distributors, pharmaceutical companies, and hospital groups. It operates through Manufacturing, Hospital, and Distribution and Others segments. The Manufacturing segment produces and sub-contracts a range of medical consumables, including patients' apparel, disposable surgical masks, boot covers and surgical gowns, underpads, adult diapers, crochet blankets, bed linens, and medical bandages. Its Hospital Services segment offers laundry and leasing services to hospitals that outsource its non-critical functions. The Distribution segment markets Medtecs-branded medical consumables to hospitals, pharmacies, and other end users, as well as through online channels. This segment also supplies other branded medical supplies and equipment comprising wheelchairs, syringes, nebulizers, and blood pressure monitors. In addition, the company manufactures, leases, trades in, and sells woven and knitted medical textile products; provides personal protective equipment, nitrile gloves, garters, and other garment products, as well as logistics and procurement services; trades in hospital textiles and garments, pillow cases, bed sheets, gowns, and other apparel products; sells hygiene products; and engages in subleasing activities. It operates in the Philippines, Singapore, Cambodia, China, Bermuda, Taiwan, Luxembourg, the United States, the United Kingdom, and internationally. Medtecs International Corporation Limited was founded in 1989 and is headquartered in Taipei, Taiwan.
Stock analysis
Medtecs International Corporation Ltd DRC (9103) currently trades at 4.97 TWD, while our model-based Fair Value estimate is 1.92 TWD, implying the stock looks roughly 158.9% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: 1.27 TWD (bear) to 2.40 TWD (bull), the price of 4.97 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Medtecs International Corporation Ltd DRC reported revenue of $78.4M in FY2025 versus $144M in FY2021, a compound −14.1%/yr. Reported net income was −$4.8M in FY2025.
Key figures
Market cap 2.7B TWD (≈ $85.3M) · P/S ratio 36.5 · EPS (TTM) −0.2800 TWD · Net margin −6.1% · Return on equity −4.6% · Return on assets (EBIT) −9.5% · Operating margin −16.7% · Revenue (TTM) $79.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −13% fair-value upside, at −61%, 9103 screens richer than that median.
Fair Value models
Bear 1.27 TWDFair Value 1.92 TWDBull 2.40 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+44.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−27.8%
Start year 2020 (pandemic). Over 10 years: +2.4% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
34.1% (2020) → −8.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Medtecs International Corporation Ltd DRC with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 204 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside−61% · Bottom 25%
Profitability
Return on assets−3% · Bottom 25%
Net margin (TTM)−6% · Bottom 25%
Operating margin (TTM)−17% · Bottom 25%
Growth and dividend
Revenue growth47% · Top 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B0.84× · Cheapest 25%
P/S (TTM)1.08× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)100· sector 31
PAST (return on equity)0· sector 25
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medtecs International Corporation Ltd DRC Fair Value". https://www.fairvalue-calculator.com/stock/9103
Frequently asked questions
Is Medtecs International Corporation Ltd (9103) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1.92 TWD versus a price of 4.97 TWD, about −61% upside (overvalued).
What is the fair value of 9103?
Our model-based fair value for Medtecs International Corporation Ltd DRC is 1.92 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 4.97 TWD.
What is the quality score of 9103?
Medtecs International Corporation Ltd DRC has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medtecs International Corporation Ltd (9103)?
Our model-based price target is the fair value of 1.92 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 1.27 TWD, optimistic scenario 2.40 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Medtecs International Corporation Ltd DRC stock forecast for 2026?
Our models put fair value at 1.92 TWD, about −61% upside versus a price of 4.97 TWD (overvalued). Cautious scenario 1.27 TWD, optimistic scenario 2.40 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Medtecs International Corporation Ltd (9103)?
Medtecs International Corporation Ltd DRC reported trailing-twelve-month revenue of about $79.0M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Medtecs International Corporation Ltd (9103)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medtecs International Corporation Ltd DRC it is 1.92 TWD per share (as of Sep 24, 2026), against a price of 4.97 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Medtecs International Corporation Ltd DRC stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 9103 trades above its calculated fair value: price 4.97 TWD, fair value 1.92 TWD, a gap of about −61% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9103?
No. The price is what the market pays today (4.97 TWD); the fair value is what the company's own numbers justify (1.92 TWD). For Medtecs International Corporation Ltd DRC the two are 3.05 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Medtecs International Corporation Ltd DRC worth?
The market values Medtecs International Corporation Ltd DRC at about 2.7B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 4.97 TWD; our models calculate a fair value of 1.92 TWD per share.
What do the bullish and bearish scenarios say about 9103?
Our models span a range for Medtecs International Corporation Ltd DRC: cautious scenario 1.27 TWD, base 1.92 TWD, optimistic 2.40 TWD per share (as of Sep 24, 2026, price 4.97 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medtecs International Corporation Ltd (9103)?
Balance-sheet figures for Medtecs International Corporation Ltd DRC (as of Sep 24, 2026): return on equity −4.6%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 9103 from its 52-week high?
Medtecs International Corporation Ltd DRC trades at 4.97 TWD, about 22% below its 52-week high of 6.39 TWD and 14% above the low of 4.36 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 1.92 TWD is for.
Which stocks are comparable to Medtecs International Corporation Ltd DRC?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medtecs International Corporation Ltd DRC stock attractive at the current price?
The data as of Sep 24, 2026: price 4.97 TWD, calculated fair value 1.92 TWD (−61%), Quality Score 57/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9103 calculated?
We run Medtecs International Corporation Ltd DRC through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.92 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Medtecs International Corporation Ltd DRC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medtecs International Corporation Ltd (9103)?
The closing price on Sep 24, 2026 was 4.97 TWD. Our model-based fair value is 1.92 TWD, about −61% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medtecs International Corporation Ltd DRC right now?
The price sits above even our optimistic bull case (2.40 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (1.27 TWD to 2.40 TWD) leaves room in how you read the outcome.
Key figures of Medtecs International Corporation Ltd DRC
How large is the market capitalisation of Medtecs International Corporation Ltd (9103)?
The market capitalisation of Medtecs International Corporation Ltd DRC is 2.7B TWD (≈ $85.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medtecs International Corporation Ltd (9103)?
The price-to-sales ratio of Medtecs International Corporation Ltd DRC is 36.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medtecs International Corporation Ltd (9103)?
Earnings per share at Medtecs International Corporation Ltd DRC are −0.2800 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medtecs International Corporation Ltd (9103)?
The net margin of Medtecs International Corporation Ltd DRC is −6.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medtecs International Corporation Ltd (9103)?
The return on equity (ROE) of Medtecs International Corporation Ltd DRC is −4.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medtecs International Corporation Ltd (9103)?
On an EBIT basis the return on assets of Medtecs International Corporation Ltd DRC is −9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medtecs International Corporation Ltd (9103)?
The operating margin of Medtecs International Corporation Ltd DRC is −16.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medtecs International Corporation Ltd (9103)?
Revenue at Medtecs International Corporation Ltd DRC is growing +47.2% versus a year earlier (3y avg +11.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medtecs International Corporation Ltd (9103)?
Earnings per share at Medtecs International Corporation Ltd DRC are growing −50.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Medtecs International Corporation Ltd (9103) generate?
The free cash flow of Medtecs International Corporation Ltd DRC is −$5.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medtecs International Corporation Ltd (9103) carry?
The net debt of Medtecs International Corporation Ltd DRC is $6.2M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medtecs International Corporation Ltd DRC in the live analysis
One click puts Medtecs International Corporation Ltd DRC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
